Expertise in
2
conditions

Wulfran Cacheux

Annemasse, FR 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
2
conditions
Annemasse, FR 
OverviewLocationsClinical Research

Overview

Wulfran Cacheux practices in Annemasse, France. Cacheux is highly rated in 2 conditions, according to our data. Their top areas of expertise are Anal Cancer, Colorectal Cancer, Human Papillomavirus Infection, Cervical Cancer, and Colostomy.

Their clinical research consists of co-authoring 46 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Locations

Annemasse, France
Other Locations
Paris, 75248, France
Rene, France
Versailles, France
Saint Cloud, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Two-period, Multicenter, Randomized, Open-label, Phase II Study Evaluating the Clinical Benefit of a Maintenance Treatment Targeting Tumor Molecular Alterations in Patients With Progressive Locally-advanced or Metastatic Solid Tumors
A Two-period, Multicenter, Randomized, Open-label, Phase II Study Evaluating the Clinical Benefit of a Maintenance Treatment Targeting Tumor Molecular Alterations in Patients With Progressive Locally-advanced or Metastatic Solid Tumors
Enrollment Status: Recruiting
Publish Date: August 07, 2025
Intervention Type: Drug, Combination product
Study Drugs: Nilotinib, Everolimus, Sorafenib, Lapatinib, Pazopanib, Olaparib, Durvalumab, Tremelimumab
Study Phase: Phase 2
A Randomized, Phase II Study Comparing the Sequences of Regorafenib and Trifluridine/Tipiracil, After Failure of Standard Therapies in Patients With Metastatic Colorectal Cancer
A Randomized, Phase II Study Comparing the Sequences of Regorafenib and Trifluridine/Tipiracil, After Failure of Standard Therapies in Patients With Metastatic Colorectal Cancer
Enrollment Status: Terminated
Publish Date: March 30, 2025
Intervention Type: Drug
Study Drugs: Regorafenib, Trifluridine/Tipiracil
Study Phase: Phase 2
View 1 Less Clinical Trial

46 Total Publications

Pathogenic alterations in PIK3CA and KMT2C are frequent and independent prognostic factors in anal squamous cell carcinoma treated with salvage abdominoperineal resection.
Pathogenic alterations in PIK3CA and KMT2C are frequent and independent prognostic factors in anal squamous cell carcinoma treated with salvage abdominoperineal resection.
Journal: International journal of cancer
Published: May 22, 2023

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Cacheux's expertise for a condition
ConditionClose
    View All 7 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile